Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk

Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk

In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to include adults aged 50 to 59 who face a heightened risk from respiratory syncytial virus (RSV) due to underlying health conditions. This expanded approval marks a significant move in Canada’s battle against RSV, a respiratory virus that, […]

GSK to acquire Aiolos Bio to expand respiratory treatment portfolio

GSK to acquire Aiolos Bio to expand respiratory treatment portfolio

GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) have announced a significant agreement, where GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focusing on respiratory and inflammatory conditions. The acquisition, valued at $1 billion upfront and potential regulatory milestone payments of up to $400 million, signifies GSK’s commitment to addressing the unmet needs of […]

Wave Life Sciences, GSK partner on oligonucleotide-based gene therapies

Wave Life Sciences, GSK partner on oligonucleotide-based gene therapies

Wave Life Sciences and GSK have forged a partnership to discover and develop oligonucleotide therapeutics, focusing on new genetic targets, for respiratory diseases. The discovery collaboration with an initial four-year research term is expected to advance Wave Life Sciences’ preclinical RNA editing program, WVE-006, to treat alpha-1 antitrypsin deficiency (AATD), a disease that impacts the […]